



30th April 2026

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500674

The Secretary,
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block Bandra-Kurla Complex
Bandra East Mumbai 400 050
Symbol: SANOFI

Sub: Press Release

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed press release titled "Sanofi India Limited appoints Mr. Rahul Bhatnagar as the Chairman of its Board of Directors".

Kindly take the above information on record.

Thanking you,

Yours faithfully

For **Sanofi India Limited**

Haresh Vala
Company Secretary & Compliance Officer
Membership No: A18246

Encl: a/a

Sanofi India Limited appoints Rahul Bhatnagar as the Chairman of its Board of Directors

Rahul Bhatnagar succeeds Aditya Narayan, who completed a decade-long distinguished tenure

Mumbai, India: 30th April 2026. Sanofi India Limited (SIL) has appointed **Mr. Rahul Bhatnagar** as the **Chairman of its Board of Directors** with effect from Thursday, 30th April 2026.

Since joining SIL's Board in 2020, Mr. Bhatnagar has actively contributed across multiple Committees, including Audit, Nomination and Remuneration, Corporate Social Responsibility, and Risk Management. He brings extensive expertise in finance, strategy and governance.

A Chartered Accountant and Wharton MBA, he has held leadership positions across leading global and Indian organizations, including Nestlé, PepsiCo, and the Bharti Group. He currently serves as an Independent Director on the Boards of Whirlpool India Limited, Rossell India Limited, TBO TEK Limited & Tasty Bite Eatables Limited.

The Board extends its sincere gratitude to Independent Director **Mr. Aditya Narayan** for his exemplary stewardship over the past decade, which has significantly strengthened SIL's corporate governance framework.

The Board also placed on record its deep appreciation for Independent Director **Mrs. Usha Thorat**, whose tenure ended at the close of business hours on 29th April 2026. We thank her for her invaluable contributions, guidance and services during her association with the Company.

The Board warmly welcomes Mr. Bhatnagar to his new role and is confident that his strategic vision will drive continued growth and excellence, as SIL advances its mission to chase the miracles of science.

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building. Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top[®] Employers Institute' – a global authority that honours excellence in people practices from 2019-2024, Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: www.sanofi.com/en/in, [LinkedIn](#) and [Twitter](#).

Media Relations

Vinifer Gandhi | vinifer.gandhi@sanofi.com